Analyst Soumit Roy from JonesTrading maintained a Buy rating on Adicet Bio and keeping the price target at $5.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Soumit Roy has given his Buy rating due to a combination of factors related to Adicet Bio’s promising clinical developments and strategic plans. The company is poised for significant updates in 2026, including Phase 1 data releases for lupus nephritis (LN), systemic lupus erythematosus (SLE), and systemic sclerosis (SSc), as well as the initiation of a pivotal trial with ADI-001 in LN following an FDA meeting. These developments indicate a strong pipeline and potential for successful outcomes, which are key drivers for the Buy rating.
Adicet Bio has demonstrated positive early results, particularly with their CD20 targeting CAR γδ T cells (ADI-001) in LN and SLE, where a notable percentage of patients achieved renal responses. The company’s strategic focus on expanding into SLE and aligning trial designs with industry peers further supports the potential for regulatory approval. Additionally, Adicet’s financial position, with substantial cash reserves, provides a solid foundation for advancing their clinical programs, reinforcing the Buy recommendation.
According to TipRanks, Roy is an analyst with an average return of -17.3% and a 26.41% success rate. Roy covers the Healthcare sector, focusing on stocks such as Protara Therapeutics, CervoMed, and Cullinan Management.
In another report released on November 7, H.C. Wainwright also maintained a Buy rating on the stock with a $9.00 price target.